A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)

ConditionsOverweight Obesity Overweight and/or Obesity Overweight or Obesity Overnutrition Nutrition Disorders Nutritional and Metabolic Diseases Body Weight

Trial statusRecruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18+

SponsorPfizer

About this trial

This study is being done to learn about the safety and effects of the study drugs, PF-08653945 and PF-08653944, when given alone or together for weight loss, compared to a placebo (a dummy drug that has no active ingredient in it).

Eligibility criteria

Qualifiers

adults aged 18 years or older with

obesity (BMI of 30.0 kg/m2 to 50.0 kg/m2) or with

overweight (BMI of 27.0 kg/m2 to <30.0 kg/m2) who also have at least 1 prespecified weight-related comorbidity (hypertension, dyslipidemia, cardiovascular disease, or obstructive sleep apnea), at the screening visit.

Disqualifiers

None

Trial design

Treatments tested in this trial

PF-08653945
PF-08653944
Placebo

Treatment groups

872 Participants

are divided into 3 treatment groups

Locations

Arizona

Arizona Clinical Trials-Chandler85225, Chandler United States

Clinical Research Institute of Arizona85375, Sun City West United States

Arizona Clinical Trials (ACT) - Tucson85711, Tucson United States

California

Ark Clinical Research92708, Fountain Valley United States

Sponsors and collaborators

Pfizer

Lead sponsor

Source ClinicalTrials.gov